The GLP-1 Revolution Meets the Middle East's Obesity Crisis: A Comprehensive Overview
A single injection once a week for major weight loss. That is the promise of medications known as GLP-1 receptor agonists, which are transforming obesity treatment globally. In the Middle East, their popularity is not just a global trend but a response to a pressing public health challenge.
The Obesity Crisis in the Middle East
Obesity rates in the Gulf Cooperation Council (GCC) countries have been on a sharp rise, with a 2022 study revealing alarming statistics. The study, published in the Journal of Obesity, found that 21.2% of people in the Middle East are obese, while 33.1% are overweight. Gender disparities are stark, with women consistently facing higher obesity rates than men across several countries.
In Kuwait, studies between 2014 and 2019 showed obesity rates among women ranging from 48% to 55%, compared to 36% to 43% among men, highlighting a persistent gender gap in obesity prevalence.
GLP-1 Medications: Beyond the Quick Fix
Despite criticism on social media, medical experts in the region emphasize that GLP-1 medications like Ozempic and Mounjaro offer more than just cosmetic weight loss. Dr. Jomana Karim, a family medicine practitioner in Dubai, explains that these medications address serious metabolic risks linked to obesity, reducing the rate of obesity-related cancers and improving fatty liver disease and metabolic syndrome.
Unlike liposuction, which removes subcutaneous fat, GLP-1 drugs target visceral fat, the dangerous internal fat surrounding vital organs.
Scientific Evidence and Benefits
Regional and international studies provide compelling evidence of GLP-1 therapies' effectiveness. A 2024 study from King Abdulaziz University in Saudi Arabia found that patients using GLP-1 medications lost an average of 10.11kg. This aligns with major international trials, such as the Step-1 trial, which showed a 15% reduction in body weight over 68 weeks for those without diabetes.
Another significant study, the 'Select' trial, published in 2023, revealed that semaglutide reduced the risk of major heart attacks and strokes in overweight patients with cardiovascular disease, even in those without diabetes.
Additional research has highlighted broader metabolic benefits, including reduced cholesterol levels, as found in a 2024 study comparing different GLP-1 receptor agonists.
Caution and Counterpoints
Despite promising results, researchers caution against overuse and highlight the need for tailored treatment. Sabina Semiz, a professor at Khalifa University, emphasizes the importance of further research to understand GLP-1 therapies' impact on diverse Arab populations.
The high cost of GLP-1 therapies limits access for lower-income groups, and there is no widely published regional registry to measure specific complications. Ali Hashemi, co-founder and CEO of Metabolic, warns against bypassing medical supervision, emphasizing the importance of a structured clinical program.
Challenges and Side Effects
Staying on GLP-1 treatment can be challenging due to high costs, supply shortages, and side effects like nausea. Hashemi highlights dangers beyond typical side effects, including wrong patient selection, titration, missed contraindications, and counterfeit drugs.
Other reported side effects include headaches, reflux, constipation, and irritation at the injection site. Some patients experience dizziness or fatigue, which may be linked to reduced protein intake.
Lifestyle Changes and Long-Term Weight Management
Even with medication, long-term weight loss depends on lifestyle changes. Research suggests that without resistance training and adequate protein intake, patients may lose lean muscle alongside fat. Appetite suppression alone is rarely sufficient for healthy, sustainable results.
Hashemi warns that the drug's effectiveness can lead to accidental under-eating and cessation of training, resulting in 'lighter' rather than 'healthier' weight loss.
Overcoming the Weight Loss Challenge
GLP-1 therapy is likened to 'renting a different physiology,' temporarily altering hunger hormones. Building sustainable habits during treatment can help patients maintain weight loss post-medication discontinuation.
The health crisis has broader implications, with obesity potentially costing the UAE nearly 5% of its GDP by 2035, according to the World Obesity Federation.
Looking Ahead: Next-Generation Treatments
Researchers are developing next-generation drugs that mimic multiple metabolic hormones, potentially reshaping metabolic disease treatment in the future.
